BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...joins the RNAi company from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), where he was SVP, head of U.S. Immune Regulation Ltd. named...
BioCentury | Sep 22, 2020
Finance

Sept. 21 Quick Takes: venture funding for Novellus, Immune Regulation, XWPharma and CoreMap

...including BRAF fusions and certain BRAF-mutated gliomas. Immune Regulation raises $53.4M B roundImmune Regulation Ltd. (formerly Peptinnovate...
...and OrbiMed Venture Partners, as well as new undisclosed strategic, corporate and financial investors. Danielle Golovin Novellus Ltd. Immune Regulation Ltd. XWPharma...
BioCentury | Jul 27, 2015
Company News

Peptinnovate, MRC deal

...Therapeutics Discovery in cellular models of bone physiology. The companies declined to disclose financial details. Peptinnovate...
Items per page:
1 - 3 of 3
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...joins the RNAi company from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), where he was SVP, head of U.S. Immune Regulation Ltd. named...
BioCentury | Sep 22, 2020
Finance

Sept. 21 Quick Takes: venture funding for Novellus, Immune Regulation, XWPharma and CoreMap

...including BRAF fusions and certain BRAF-mutated gliomas. Immune Regulation raises $53.4M B roundImmune Regulation Ltd. (formerly Peptinnovate...
...and OrbiMed Venture Partners, as well as new undisclosed strategic, corporate and financial investors. Danielle Golovin Novellus Ltd. Immune Regulation Ltd. XWPharma...
BioCentury | Jul 27, 2015
Company News

Peptinnovate, MRC deal

...Therapeutics Discovery in cellular models of bone physiology. The companies declined to disclose financial details. Peptinnovate...
Items per page:
1 - 3 of 3